 CRANFORD, N.J., July 7, 2021 PRNewswire -- Citius Pharmaceuticals, Inc. Citius or the Company Nasdaq: CTXR, a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today provided a business update for the six-month period ended June 30, 2021 and reported on recent corporate developments. 